Posted by Michael Wonder on 23 Dec 2020
The European Commission approves Zogenix’s Fintempa (fenfluramine) oral solution for the treatment of seizures in Dravet syndrome
21 December 2020 - First EU market launch planned for Germany in Q1 2021.
Zogenix announced today that the European Commission has granted marketing authorization for Fintempla (fenfluramine) oral solution for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients two years of age and older.
